Analysts Set Catalyst Biosciences (CBIO) PT at $40.00

Catalyst Biosciences (NASDAQ:CBIO) has been assigned an average recommendation of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $40.00.

Several analysts have weighed in on CBIO shares. Zacks Investment Research upgraded Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Wednesday, April 25th. Chardan Capital boosted their price objective on Catalyst Biosciences from $10.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, February 9th. BidaskClub downgraded Catalyst Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, March 29th. B. Riley set a $44.00 price objective on Catalyst Biosciences and gave the company a “buy” rating in a research report on Monday, May 14th. Finally, ValuEngine upgraded Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

In other news, major shareholder James E. Flynn sold 52,461 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $30.87, for a total transaction of $1,619,471.07. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider James E. Flynn sold 71,778 shares of the business’s stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $30.53, for a total value of $2,191,382.34. The disclosure for this sale can be found here. Insiders own 3.14% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Ardsley Advisory Partners purchased a new position in shares of Catalyst Biosciences during the fourth quarter valued at approximately $205,000. Wells Fargo & Company MN increased its stake in shares of Catalyst Biosciences by 148.3% during the first quarter. Wells Fargo & Company MN now owns 8,940 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 5,340 shares during the period. Spark Investment Management LLC purchased a new position in shares of Catalyst Biosciences during the first quarter valued at approximately $330,000. Geode Capital Management LLC purchased a new position in shares of Catalyst Biosciences during the fourth quarter valued at approximately $379,000. Finally, Raymond James & Associates purchased a new position in shares of Catalyst Biosciences during the fourth quarter valued at approximately $585,000. 76.55% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CBIO stock opened at $29.03 on Friday. Catalyst Biosciences has a fifty-two week low of $3.11 and a fifty-two week high of $37.00. The company has a market capitalization of $337.41 million, a price-to-earnings ratio of -3.90 and a beta of 2.48.

Catalyst Biosciences (NASDAQ:CBIO) last announced its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.41) by $0.45. Catalyst Biosciences had a negative return on equity of 39.27% and a negative net margin of 2,983.40%. The firm had revenue of $0.32 million during the quarter, compared to the consensus estimate of $0.23 million. equities research analysts forecast that Catalyst Biosciences will post -2.71 EPS for the current fiscal year.

About Catalyst Biosciences

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply